From: Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia
miRNAs | Genetic abnormalities | Altered expression | Targets | Function | Reference |
---|---|---|---|---|---|
miR-9 | t(8;21)(q22;q22.1) RUNX1-RUNX1T1; mutated NPM1; biallelic mutations of CEBPA | ↑in MLL-rearranged AML | RHOH RYBP | miR-9 was upregulated by MLL-AF9 and increased MLL-AF9-mediated cell transformation in murine hematopoietic progenitor cells in vitro and in vivo. Mice transplanted with BM progenitors that overexpressed both MLL-AF9 and miR-9 (MLL-AF9+ miR-9) had higher frequency of c-Kit+ blast cells in the BM, spleen, and peripheral blood than MLL-AF9 mice. Moreover, MLL-AF9+ miR-9 leukemic cells had a higher frequency of immature blasts | [11] |
↓in t(8;21) AML | HMGA2 LIN28B | Increase proliferation and decrease monocytic differentiation | [12] | ||
↓in RUNX1-RUNX1T1(+)AML | RUNX1, RUNX1T1, RUNX1-RUNX1T1 | RUNX1-RUNX1T1 triggered the heterochromic silencing of miR-9-1, resulting in hypermethylation of the miR-9-1 promoter in t(8; 21) AML. Silencing of miR-9-1 promoted expression of target genes(RUNX1, RUNX1T1, and RUNX1-RUNX1T1), which inhibited differentiation and promoted the proliferation of t(8; 21) AML cell lines | [13] | ||
↑3YPERLINK \lline | ERG | ERG is a direct target of miR-9 which contributed to miR-9/9*-induced differentiation of progenitor cells towards neutrophils | [33] | ||
↑3YPERLINK \l "_ENREF_33" \o "Nowek K, 2016 #298" hor><Yeaparients with normal karyotype | Hes1 | miR-9 negatively regulated Hes1 expression and knockdown of miR-9 suppressed the proliferation of AML cells by the induction of G0 arrest and apoptosis in vitro, decreased circulating leukemic cell counts in peripheral blood and bone marrow, attenuated splenomegaly, and prolonged survival in a xenotransplant mouse model | [34] | ||
↓in AE-positive cell lines | SIRT1 | Knockdown of SIRT1 expression inhibits cell proliferation in AE-positive AML cell lines | [87] | ||
↓in EVI1-induced AML | FOXO1 FOXO3 | Increase proliferation and decrease monocytic differentiation | [88] | ||
miR-21 | Mutated NPM1; mutated RUNX1 | ↑in K562/DNR | PTEN | Decreased cell sensitivity to daunorubicin | [42] |
↑in SKM-1 cell | PTEN/AKT pathway | Downregulation of miR-21 expression inhibits proliferation and induces G1 arrest and apoptosis in SKM-1 cell | [89] | ||
miR-22 |  | ↓iR-22LINK \l " | CRTC1 FLT3 MYCBP | Represses the CREB and MYC pathways | [90] |
miR-29b | PML-RARA; mutated NPM1 | ↑in K562 cells | DNMT3A DNMT3B DNMT1 | Increase DNA methylation and hypermethylation | [49] |
↓in t(8;21) AML | SP1 | Upregulate KIT contributing to malignant proliferation | [54] | ||
↓in various subtypes of AML | AKT2 CCND2 | Increase cell growth, leukemic progression in vivo | [91] | ||
↓in various subtypes of AML | MCL-1 CXXC6 CDK6 | Increase cell growth, decrease apoptosis, leukemic progression in vivo | [92] | ||
↓in various subtypes of AML | SP1 DNMT3A DNMT3B | Results in global DNA hypermethylation | [93] | ||
↑in NK cells |  | Damage to NK cells development and function | [94] | ||
miR-34a | Biallelic mutations of CEBPA | ↓in CEBPA mutated AML | E2F3 | Increase proliferation and decrease differentiation | [95] |
↓in de novo AML | PDL1 | Immune dysregulation | [96] | ||
↓in CEBPA mutated AML cell lines | HMGB1 | Inhibit cell apoptosis and increased autophagy | [97] | ||
miR-34b |  | ↓iR-34bINK \l "_ENREF_ | CREB | Survival signaling pathways | [98] |
miR-34c-5p |  | ↓in LSCs | RAB27B | Increase miR-34c-5p expression induced LSCs senescence ex vivo |  |
miR-99a | Mutated RUNX1; inv(16)(p13.1q22) or t(16;16) (p13.1;q22) | Â | Â | High miR-99a expression could predict worse outcome in AML patients undergoing allo-HCST | [80] |
↑in initial diagnosis and relapse |  | Regulate self-renewal, inhibiting differentiation and cell cycle entry | [99] | ||
↑in AML-AF9 | SMARCA5 HS2ST3 HOXA1 | Increase proliferation, colony formation, cell survival, inhibite differentiation | [100] | ||
↑in pediatric-onset AML (M1–M5) | CTDSPL TRIB2 | Increase proliferation, colony formation, cell survival | [101] | ||
miR-103 |  | ↑in K562 cells | COP1 | Increase drug resistance of K562 cells to ADR | [102] |
miR-125b | t(8;21)(q22;q22.1) RUNX1-RUNX1T1; PML-RARA; mutated NPM1 | ↑in MDS and AML with t(2;11) (p21;q23) |  | Inhibit differentiation | [103] |
↑in AML | LIN28A | Uncontrolled generation of myeloid cells | [104] | ||
 | IRF4 | Induce myeloid leukemia in mice by inducing immortality, self-renewal, and tumorigenesis in myeloid progenitors | [105] | ||
↑in pediatric AML | FES PU.1 | Block monocytic differentiation of AML in vitro | [106] | ||
↑in AML cell lines | NF-κB | Inhibits human AML cells invasion, proliferation and promotes cells apoptosis | [107] | ||
miR-126 | t(8;21)(q22;q22.1) RUNX1-RUNX1T1; PML-RARA; mutated NPM1 | ↑in t(8;21) and inv(16) AML | PLK2 | Inhibits cell apoptosis and increase cell viability | [108] |
↑in LSCs of AML |  | Increase leukemic growth, and survival of leukemic stem and progenitor cells in vivo | [109] | ||
↑in t(8;21) AML | ERRFI1 SPRED1 FZD7 | Both gain and loss of function of miR-126 promotes leukemogenesis in vivo through targeting distinct gene signaling | [110] | ||
↑in LSC of CN-AML |  | Increase LSC maintenance and self-renewal | [111] | ||
↑in LSCs of AML | ADAM9, ILK, GOLPH3, CDK3, TOM1 | Increase LSC maintenance and self-renewal, quiescence, chemotherapy resistance in vivo | [112] | ||
↑in AML cell lines | TRAF7 | Suppresses apoptosis by downregulating TRAF7, which blocks the c-FLIP pathway | [113] | ||
miR-135a |  | ↓in AML | HOXA10 | Overexpression of miR-135a inhibits the proliferation and cell cycle and promotes cellular apoptosis | [70] |
miR-139-5p |  | ↓iR-139-5p \l "_E | EIF4G2 | Repressing the translation initiation, specifically inducing the translation of cell cycle inhibitor p27 Kip1 | [114] |
miR-143 |  | ↑inCD34 + HSPCs | ERK5 | Increase granulocyte surface marker Ly6G and a more mature morphology toward granulocytes induces apoptosis | [115] |
miR-144-3p |  | ↑iR-144-3pnn JU, 2018 #227" e | NRF2 | Antiapoptotic | [116] |
miR-146a | t(8;21)(q22;q22.1)RUNX1-RUNX1T1; mutated NPM1 | ↓in del(5q) MDS | TIRAP TRAF6 | Inappropriate activation of innate immune signaling in HSPCs and megakaryocytic abnormalities | [117] |
Knockout in del(5q)MDS/AML |  | Increase cell survival and proliferation of propagating cells through the TRAF6/p62/NF-κB complex | [118] | ||
 | IRAK1 | miR-146a knockout mice develop myeloid and lymphoid malignancies | [119] | ||
 |  | miR-146a deletion leads to myeloproliferation in mice |  | ||
Knockout in del(5q) MDS/AML | Â | Co-deletion of TIFAB and miR-146a may cooperate to induce TRAF6 signaling contributing to ineffective hematopoiesis | [120] | ||
 |  | miR-146a/Traf6 axis controls autoimmunity and myelopoiesis in mice | [121] | ||
↑in elderly AML patients | CXCR4 Smad4 | Suppress the migration abilities of leukemia cells and promote cell cycle entry in leukemia cells | [122] | ||
miR-149-5p |  | ↑iR-149 | FASLG | Targeting FASLG led to suppression on cell apoptosis | [123] |
miR-150 | PML-RARA | ↓in various subtypes of AML | NANOG | Increase proliferation, colony, and sphere formation, increase tumor growth in vivo | [124] |
↓in various subtypes of AML | EIF4B, FOXO4, PRKCA, TET3 | Increase cell growth and inhibits apoptosis in vitro and in vivo | [125] | ||
enriched in Molm-14 exosomes | CXCR4 | Decrease migration of Ba/F3 cells and the surface expression of CXCR4 | [60] | ||
miR-150 miR-155 | Â | enriched in exosomes isolated from cultured AML cells | c-MYB | Hematopoiesis is suppressed by releasing exosomes that contain miR-150/miR155 targeting c-MYB | [59] |
miR-181a |  | ↑iR-181aNK \l "_ENREF_59"AML patients | KRAS, NRAS, and MAPK1 | Targeting the RAS-MAPK-pathway | [126] |
miR-182-5p | PML-RARA; Mutated NPM1; FLT3-ITD | ↑in AML cell lines and patients blood sample | BCL2L12 BCL2 | Promote cell proliferation, and reverse cisplatin (DDP) resistance | [40] |
↑in APL | CEBPα | Induce apoptosis | [127] | ||
miR-192 |  | ↓in various subtype of AML | CCNT2 | Increase proliferation and cell cycling, decrease differentiation | [128] |
miR-193a |  | ↓iR-AML1/ETO-positive leukemia cells | PTEN/PI3K signal pathway | AML1/ETO triggers the heterochromatic silencing of microRNA-193a (miR-193a) by binding at AML1-binding sites and recruiting chromatin-remodeling enzymes, which expands the oncogenic activity of AML-ETO, resulting in leukemogenesis | [35] |
miR-193b | Biallelic mutations of CEBPA; mutated NPM1 | ↓mutati | CCND1,KIT, KRAS, or SOS2 | Apoptosis and a G1/S-phase block | [74] |
miR-196b | t(9;11)(p21.3;q23.3) MLLT3-KMT2A; mutated NPM1 | ↑in MLL associated AML |  | Increase proliferation and survival, and decrease differentiation and replating potential | [129] |
↑in MLL-associated AML | HOXA9 Meis1 FAS | Inhibit differentiation, promote cell proliferation, and induce leukemic progression in mice | [130] | ||
miR-204 | Mutated NPM1 | ↑in AML cells | BIRC6 | Lead to AML cell apoptosis | [131] |
↑in NPMC+ AML | HOXA10 Meis1 |  | [132] | ||
miR-221 | t(8;21)(q22;q22.1) RUNX1-RUNX1T1; CBFB-MYH1; mutated NPM1 | ↑in AML | NCL/miR-221/NF-κB/DNMT1 network | Involve in DNA hypomethylation | [55] |
miR-223 | t(8;21)(q22;q22.1) RUNX1-RUNX1T1; CBFB-MYH1; PML_RARA; mutated NPM1; mutated RUNX1 | ↓in t(8;21) AML |  | Myeloid differentiation block | [133] |
↓in various subtypes of AML | E2F1 | Lead to AML cell apoptosis | [134] | ||
↓in AML with adverse prognosis |  | Impair differentiation | [135] | ||
↓in various subtypes of AML | FBXW7 | Increase cell proliferation and enhance apoptosis | [136] | ||
miR-339-5p |  | ↓in AML cells | SOX4 | Inhibit cell proliferation of AML cells | [137] |
miR-345-5p | Mutated NPM1 | ↓in AML cell lines | AKT1/2 | Facilitate the proliferation of leukemia cells | [138] |
miR-370 |  | ↓iR-370 | NF1 | Activation of the RAS signaling pathway | [139] |
miR-375 |  | ↓in AML | miR-375-HOXB3-CDCA3/ DNMT3B pathway | Involve in DNA hypomethylation | [56] |
miR-7977 |  | ↑in AML cell lines |  | miR-7977 in extracellular vesicles may be a critical factor that induces failure of normal hematopoiesis via poly(rC) binding protein 1 suppression | [61] |
miR-26a-5p, miR-101-3p |  | ↑in exosomes derived from MSCs in AML patients |  |  | [58] |
miR-23b-5p, miR-339-3p, miR-425-5p |  | ↓in exosomes derived from MSCs in AML patients |  |  | [58] |
let-7a, miR-99b, miR-146a, miR-150, miR-155, miR-191, miR -1246 | Â | Enriched in exosomes from NSG mice serum | Â | Â | [57] |
Let-7c |  | ↓in AML patients with t(8;21) and inv(16) | PBX2 | Promotes granulocytic differentiation | [140] |